Document 0103
 DOCN  M9580103
 TI    Interleukin-12 augments the generation of autologous tumor-reactive CD8+
       cytotoxic T lymphocytes from tumor-infiltrating lymphocytes.
 DT    9506
 AU    Kuge S; Watanabe K; Makino K; Tokuda Y; Mitomi T; Kawamura N; Habu S;
       Nishimura T; Department of Immunology, Tokai University School of
       Medicine,; Isehara.
 SO    Jpn J Cancer Res. 1995 Feb;86(2):135-9. Unique Identifier : AIDSLINE
       MED/95247536
 AB    Human tumor-infiltrating lymphocytes (TIL) were obtained from breast
       cancer, renal cancer or neuroblastoma to investigate the generation of
       autologous tumor-reactive CD8+ cytotoxic T lymphocytes (CTL). When TIL
       were cultured with interleukin (IL)-2 (100 U/ml), the growth of TIL
       peaked around 8-10 days after the initiation of culture. In contrast,
       the proliferation of TIL cultured with IL-2 plus IL-12 peaked around 4-5
       days after culture and tumor cells rapidly disappeared from the culture.
       To determine the generation of autologous tumor-reactive CD8+ CTL,
       TIL-derived CD8+ T cells were separated by FACStar. Both IL-2-activated
       and IL-2 plus IL-12-activated TIL-CD8+ T cells showed the same level of
       lymphokine-activated killer activity against a variety of tumor cells.
       However, TIL-CD8+ T cells activated with IL-2 plus IL-12 revealed
       greatly augmented cytotoxicity against autologous tumor cells compared
       with that induced by IL-2 alone. The autologous tumor cell-killing
       activity of TIL-CD8+ CTL was significantly inhibited by the addition of
       F(ab)2 anti-CD3 monoclonal antibody, indicating that these CTL recognize
       autologous tumor antigen through T cell receptor. These results imply
       that IL-12 is a novel cytokine which facilitates the generation of
       autologous tumor-reactive CD8+ CTL from TIL.
 DE    CD8-Positive T-Lymphocytes/*DRUG EFFECTS  Human
       Interleukin-12/*PHARMACOLOGY  Interleukin-2/PHARMACOLOGY  Lymphocytes,
       Tumor-Infiltrating/*DRUG EFFECTS  Support, Non-U.S. Gov't  Tumor Cells,
       Cultured  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).